Vice President, Head of Global Regulatory Affairs
Rain Therapeutics Inc.
Tina Kim-Hafken, MS is Vice President, Head of Global Regulatory Affairs at Rain Therapeutics Inc. She has over 20 years of combined R&D and global regulatory experience in both CMC and in the oncology therapeutic area with a strong track record of leading global marketing and clinical trial applications, negotiating innovative strategies and delivering regulatory approvals. Prior to joining Rain Therapeutics, Tina was Senior Director of Regulatory Science and Global Regulatory Lead at Seagen Inc. where she successfully led the submission and approval of TUKYSA® (tucatinib) for metastatic HER2-postive breast cancer in the United States, European Union, United Kingdom, Switzerland, Singapore, Canada, and Australia. Before Seagen, Tina spent 12 years at Amgen Inc. serving as Global Regulatory CMC Lead for Aranesp® (darbepoetin alfa) and EVENITY® (romosozumab). Tina holds bachelor’s degrees in Chemistry and Music from the University of Kansas and a master’s degree in Biotechnology from Johns Hopkins University.
Disclosure information not submitted.
Sunday, September 11, 2022
8:30 AM – 4:00 PM MST
Monday, September 12, 2022
9:45 AM – 11:00 AM MST